To evaluate the effects of extended-release niacin ( ERN ) / laropiprant ( LRPT ) , simvastatin ( SIMVA ) , and ERN/LRPT + SIMVA ( pooled ERN/LRPT + SIMVA ) on apoB : LDL-C and apoB : non-HDL-C correlations in dyslipidemic patients .